2.35
-0.20 (-7.84%)
| Previous Close | 2.55 |
| Open | 2.60 |
| Volume | 417,043 |
| Avg. Volume (3M) | 625,731 |
| Market Cap | 22,457,164 |
| Price / Sales | 2.72 |
| Price / Book | 7.77 |
| 52 Weeks Range | |
| Earnings Date | 25 Jul 2023 - 31 Jul 2023 |
| Profit Margin | -14.74% |
| Operating Margin (TTM) | 7.86% |
| Diluted EPS (TTM) | 1.05 |
| Quarterly Revenue Growth (YOY) | 54.00% |
| Total Debt/Equity (MRQ) | 186.77% |
| Current Ratio (MRQ) | 2.79 |
| Return on Assets (TTM) | 0.98% |
| Return on Equity (TTM) | -34.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Alimera Sciences, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.17 |
|
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 5.34% |
| % Held by Institutions | 86.54% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |